Synopsis
Synopsis
0
VMF
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 2 Propylpentanoic Acid
2. 2-propylpentanoic Acid
3. Calcium Valproate
4. Convulsofin
5. Depakene
6. Depakine
7. Depakote
8. Dipropyl Acetate
9. Divalproex
10. Ergenyl
11. Magnesium Valproate
12. Propylisopropylacetic Acid
13. Semisodium Valproate
14. Sodium Valproate
15. Valproate
16. Valproate Calcium
17. Valproate Sodium
18. Valproic Acid
19. Valproic Acid, Sodium Salt (2:1)
20. Vupral
1. 76584-70-8
2. Valproate Semisodium
3. Epival
4. Depakote
5. Sodium Divalproate
6. Semisodium Valproate
7. Sprinkle
8. Abbott 50711
9. Divalproex
10. Valdisoval
11. Valproato Semisodico
12. Delepsine
13. Valcote
14. Valparin
15. Epilex
16. Valproate Semisodique
17. Sodium Hydrogen Divalproate
18. Valproatum Seminatricum
19. Sodium Hydrogen Bis(2-propylpentanoate)
20. Pentanoic Acid, 2-propyl-, Sodium Salt (2:1)
21. Abbott-50711
22. Sodium Hydrogen Bis(2-propylvalerate)
23. Divalproex Sodium [usan:usp]
24. Divalproex (sodium)
25. Sodium;2-propylpentanoate;2-propylpentanoic Acid
26. Valproate Semisodium (inn)
27. Depakote Er
28. Chebi:4667
29. Divalproate
30. Valproic Acid (semisodium Salt)
31. Depakote Cp
32. Valproate Semisodium [inn]
33. Valproate Semisodique [french]
34. Valproato Semisodico [spanish]
35. Valproatum Seminatricum [latin]
36. Valproic Acid Semisodium Salt
37. Depakote (tn)
38. Natrium Hydrogen Bis(2-propylvalerat)
39. Valproic Acid Semisodium Salt (2:1)
40. 644vl95ao6
41. Valproic Acid Sodium Salt (2:1)
42. Divalproex Sodium (usp)
43. Unii-644vl95ao6
44. Sodium Divalproex
45. Sodium Hydrogen Bis(2-propylvalerate), Oligomer
46. Sodium; 2-propylpentanoate; 2-propylpentanoic Acid
47. Schembl40996
48. Chembl2105613
49. Sodium;hydron;2-propylpentanoate
50. Dtxsid70227388
51. Hms3651c17
52. Hms3884o06
53. Bcp12800
54. S1703
55. Sodiumhydrogenbis(2-propylpentanoate)
56. Akos015895200
57. Ccg-267581
58. As-17254
59. Db-056089
60. Ft-0625375
61. Sw219169-1
62. C76453
63. D00304
64. Ab01568255_01
65. A838751
66. Sodium 2-propylpentanoate--2-propylpentanoic Acid (1:1)
Molecular Weight | 310.40 g/mol |
---|---|
Molecular Formula | C16H31NaO4 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 10 |
Exact Mass | 310.21200375 g/mol |
Monoisotopic Mass | 310.21200375 g/mol |
Topological Polar Surface Area | 77.4 Ų |
Heavy Atom Count | 21 |
Formal Charge | 0 |
Complexity | 192 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 3 |
1 of 6 | |
---|---|
Drug Name | Depakote |
Drug Label | Divalproex sodium is a stable co-ordination compound comprised of sodium valproate and valproic acid in a 1:1 molar relationship and formed during the partial neutralization of valproic acid with 0.5 equivalent of sodium hydroxide. Chemically it is d... |
Active Ingredient | Divalproex sodium |
Dosage Form | Capsule, delayed rel pellets; Tablet, delayed release |
Route | Oral |
Strength | eq 125mg valproic acid; eq 500mg valproic acid; eq 250mg valproic acid |
Market Status | Prescription |
Company | Abbvie |
2 of 6 | |
---|---|
Drug Name | Depakote er |
Drug Label | Divalproex sodium is a stable co-ordination compound comprised of sodium valproate and valproic acid in a 1:1 molar relationship and formed during the partial neutralization of valproic acid with 0.5 equivalent of sodium hydroxide. Chemically it is d... |
Active Ingredient | Divalproex sodium |
Dosage Form | Tablet, extended release |
Route | oral; Oral |
Strength | 250mg; eq 500mg valproic acid; eq 250mg valproic acid; 500mg |
Market Status | Prescription |
Company | Abbott; Abbvie |
3 of 6 | |
---|---|
Drug Name | Divalproex sodium |
Drug Label | Divalproex sodium is a stable co-ordination compound comprised of sodium valproate and valproic acid in a 1:1 molar relationship. Chemically it is designated as sodium hydrogen bis(2-propylpentanoate). Divalproex sodium has the following structure:Di... |
Active Ingredient | Divalproex sodium |
Dosage Form | Tablet, extended release; Capsule, delayed rel pellets; Tablet, delayed release |
Route | Oral |
Strength | eq 125mg valproic acid; eq 500mg valproic acid; eq 250mg valproic acid |
Market Status | Prescription |
Company | Anchen Pharms; Wockhardt; Upsher Smith; Nu Pharm; Actavis Labs Fl; Teva; Vintage; Aurobindo Pharma; Sun Pharm Inds; Reddys; Lupin; Zydus Pharms Usa; Dr Reddys Labs; Sandoz; Orchid Hlthcare; Mylan; Unichem Labs; Impax Labs |
4 of 6 | |
---|---|
Drug Name | Depakote |
Drug Label | Divalproex sodium is a stable co-ordination compound comprised of sodium valproate and valproic acid in a 1:1 molar relationship and formed during the partial neutralization of valproic acid with 0.5 equivalent of sodium hydroxide. Chemically it is d... |
Active Ingredient | Divalproex sodium |
Dosage Form | Capsule, delayed rel pellets; Tablet, delayed release |
Route | Oral |
Strength | eq 125mg valproic acid; eq 500mg valproic acid; eq 250mg valproic acid |
Market Status | Prescription |
Company | Abbvie |
5 of 6 | |
---|---|
Drug Name | Depakote er |
Drug Label | Divalproex sodium is a stable co-ordination compound comprised of sodium valproate and valproic acid in a 1:1 molar relationship and formed during the partial neutralization of valproic acid with 0.5 equivalent of sodium hydroxide. Chemically it is d... |
Active Ingredient | Divalproex sodium |
Dosage Form | Tablet, extended release |
Route | oral; Oral |
Strength | 250mg; eq 500mg valproic acid; eq 250mg valproic acid; 500mg |
Market Status | Prescription |
Company | Abbott; Abbvie |
6 of 6 | |
---|---|
Drug Name | Divalproex sodium |
Drug Label | Divalproex sodium is a stable co-ordination compound comprised of sodium valproate and valproic acid in a 1:1 molar relationship. Chemically it is designated as sodium hydrogen bis(2-propylpentanoate). Divalproex sodium has the following structure:Di... |
Active Ingredient | Divalproex sodium |
Dosage Form | Tablet, extended release; Capsule, delayed rel pellets; Tablet, delayed release |
Route | Oral |
Strength | eq 125mg valproic acid; eq 500mg valproic acid; eq 250mg valproic acid |
Market Status | Prescription |
Company | Anchen Pharms; Wockhardt; Upsher Smith; Nu Pharm; Actavis Labs Fl; Teva; Vintage; Aurobindo Pharma; Sun Pharm Inds; Reddys; Lupin; Zydus Pharms Usa; Dr Reddys Labs; Sandoz; Orchid Hlthcare; Mylan; Unichem Labs; Impax Labs |
Anticonvulsants
Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)
Antimanic Agents
Agents that are used to treat bipolar disorders or mania associated with other affective disorders. (See all compounds classified as Antimanic Agents.)
Enzyme Inhibitors
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)
GABA Agents
Substances used for their pharmacological actions on GABAergic systems. GABAergic agents include agonists, antagonists, degradation or uptake inhibitors, depleters, precursors, and modulators of receptor function. (See all compounds classified as GABA Agents.)
Registrant Name : Sanofi-Aventis Korea Co., Ltd.
Registration Date : 2021-03-10
Registration Number : 20210310-209-J-870
Manufacturer Name : Sanofi Chimie
Manufacturer Address : Chem'pôle 64 Avenue du Lac 64150 Mourenx, France
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Certificate Number : CEP 2004-226 - Rev 05
Issue Date : 2024-02-02
Type : Chemical
Substance Number : 1378
Status : Valid
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 5678
Submission : 1985-01-18
Status : Active
Type : II
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Date of Issue : 2022-06-17
Valid Till : 2025-07-07
Written Confirmation Number : WC-0067
Address of the Firm :
NDC Package Code : 55111-875
Start Marketing Date : 2006-10-16
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Chynops Pharma is an ideal sourcing partner for high-quality APIs, advanced intermediates, speciality chemicals & excipients.
SCI Pharmtech offers high-quality, cost-effective APIs, advanced intermediates, & custom products with global expertise and precision.
GDUFA
DMF Review : Reviewed
Rev. Date : 2015-09-13
Pay. Date : 2015-09-08
DMF Number : 16558
Submission : 2003-04-28
Status : Active
Type : II
Certificate Number : R1-CEP 2003-108 - Rev 05
Issue Date : 2019-06-13
Type : Chemical
Substance Number : 1378
Status : Valid
Registration Number : 220MF10111
Registrant's Address : No. 61, Ln. 309, Haihu N. Rd. , Luzhu Dist. , Taoyuan City 33856, Taiwan
Initial Date of Registration : 2008-04-21
Latest Date of Registration : --
NDC Package Code : 68108-0234
Start Marketing Date : 2012-01-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Base Farm Co., Ltd.
Registration Date : 2022-05-17
Registration Number : 20201125-209-J-769(2)
Manufacturer Name : SCI Pharmtech, Inc
Manufacturer Address : No.61, Ln.309, Haihu N. Rd., Luzhu Dist. Taoyuan City 33856, Taiwan
Available Reg Filing : CA, CN |
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 14646
Submission : 1999-12-27
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 14646
Submission : 1999-12-27
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 5678
Submission : 1985-01-18
Status : Active
Type : II
SCI Pharmtech offers high-quality, cost-effective APIs, advanced intermediates, & custom products with global expertise and precision.
GDUFA
DMF Review : Complete
Rev. Date : 2014-12-16
Pay. Date : 2014-11-26
DMF Number : 18285
Submission : 2005-04-08
Status : Active
Type : II
SCI Pharmtech offers high-quality, cost-effective APIs, advanced intermediates, & custom products with global expertise and precision.
GDUFA
DMF Review : Complete
Rev. Date : 2015-09-13
Pay. Date : 2015-09-08
DMF Number : 16558
Submission : 2003-04-28
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4657
Submission : 1982-09-09
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 3061
Submission : 1977-11-14
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-10-31
Pay. Date : 2013-09-18
DMF Number : 6428
Submission : 1986-06-18
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 7380
Submission : 1988-03-11
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4380
Submission : 1981-10-26
Status : Inactive
Type : II
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 3322
Submission : 1978-06-20
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Certificate Number : CEP 2004-226 - Rev 05
Status : Valid
Issue Date : 2024-02-02
Type : Chemical
Substance Number : 1378
SCI Pharmtech offers high-quality, cost-effective APIs, advanced intermediates, & custom products with global expertise and precision.
SCI Pharmtech offers high-quality, cost-effective APIs, advanced intermediates, & custom products with global expertise and precision.
Certificate Number : R1-CEP 2003-108 - Rev 05
Status : Valid
Issue Date : 2019-06-13
Type : Chemical
Substance Number : 1378
Certificate Number : R1-CEP 2003-174 - Rev 03
Status : Valid
Issue Date : 2020-02-21
Type : Chemical
Substance Number : 1378
Certificate Number : CEP 2020-374 - Rev 01
Status : Valid
Issue Date : 2024-08-26
Type : Chemical
Substance Number : 1378
Certificate Number : CEP 2015-158 - Rev 01
Status : Valid
Issue Date : 2024-04-05
Type : Chemical
Substance Number : 1378
Certificate Number : R1-CEP 2004-015 - Rev 04
Status : Withdrawn by Holder
Issue Date : 2014-12-04
Type : Chemical
Substance Number : 1378
Certificate Number : R1-CEP 1998-026 - Rev 03
Status : Valid
Issue Date : 2015-08-06
Type : Chemical
Substance Number : 1378
Certificate Number : CEP 2014-140 - Rev 02
Status : Valid
Issue Date : 2024-04-02
Type : Chemical
Substance Number : 1378
Certificate Number : R1-CEP 2006-310 - Rev 04
Status : Valid
Issue Date : 2020-03-11
Type : Chemical
Substance Number : 1378
Certificate Number : R1-CEP 2001-287 - Rev 01
Status : Withdrawn by Holder
Issue Date : 2012-10-02
Type : Chemical
Substance Number : 1378
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?